Slowing progressive chronic diseases requires substituting clinical endpoints with surrogate biomarkers.
To accelerate market access for progressive kidney and endocrine conditions, regulatory systems are clearing therapies based on early surrogate biomarkers, postponing final clinical verification.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The FDA leveraged accelerated approval based on a surrogate biomarker to delay pancreatic functional decline, requiring a follow-up trial to confirm real-world clinical efficacy.
Vertex's BLA for povetacicept leverages a surrogate biomarker (proteinuria) at an interim milestone to seek accelerated approval for IgAN.
A major treatment for Stage 3 Type 1 Diabetes, an endocrine disease, was approved on the basis of a surrogate biomarker, deferring clinical confirmation to an ongoing Phase 3 study.
The first T1D kidney therapy in three decades cleared on a six-month proteinuria surrogate rather than verified long-term renal outcomes — surrogate substitution applied to diabetic kidney disease.
Otsuka is converting its early biomarker-based approval into traditional full approval using two-year clinical kidney function slope data.
The drug was approved under an accelerated pathway using proteinuria as a surrogate endpoint while long-term kidney function preservation is verified.
The FDA cleared Trutakna using the surrogate biomarker of proteinuria, leaving long-term clinical efficacy to be confirmed in later trial readouts.
Accelerated approval was granted for this progressive kidney disease by leveraging an early surrogate endpoint ahead of long-term validation.
Trutakna was cleared under the accelerated pathway based on the surrogate endpoint of proteinuria, delaying full approval until final eGFR data is evaluated.
Trutakna secured accelerated approval for a progressive kidney disease using the surrogate marker of proteinuria while awaiting confirmatory kidney function data.
Regulators cleared Bristol Myers Squibb's chronic multiple myeloma therapy using a deep surrogate biological response to accelerate market access.
The FDA's landmark approval of Zenbexus based on MRD-negativity establishes the substitution of clinical outcomes with surrogate biomarkers in progressive chronic disease settings.